ProfileGDS5678 / 1440034_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 31% 31% 32% 30% 31% 30% 30% 30% 31% 31% 30% 31% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7354431
GSM967853U87-EV human glioblastoma xenograft - Control 22.6969231
GSM967854U87-EV human glioblastoma xenograft - Control 32.7038431
GSM967855U87-EV human glioblastoma xenograft - Control 42.6669232
GSM967856U87-EV human glioblastoma xenograft - Control 52.6389130
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7779331
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7276130
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6680430
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6572230
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6899831
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6840131
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6616130
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7034931
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6899931